Kura Oncology, INC Form 4 insider transactions

Director Faheem Hasnain of Kura Oncology, Inc. reports stock transactions, including acquisitions and disposals, under a pre-arranged Rule 10b5-1 trading plan.

Thomas James Doyle, SVP of Finance & Accounting at Kura Oncology, sold a portion of his shares to cover taxes associated with the vesting of restricted stock units.

Mollie Leoni, Chief Medical Officer of Kura Oncology, sold a total of 4,963 shares of common stock on January 28, 2025, to cover taxes associated with the vesting of restricted stock units.

Kura Oncology's Chief Legal Officer, Teresa Bair, sold shares to cover taxes related to the vesting of restricted stock units.

Kura Oncology's Chief Operating Officer, Kathleen Ford, sold 1,817 shares of common stock to cover taxes related to a vesting of restricted stock units.

Kura Oncology's Chief Scientific Officer, Francis Burrows, sold shares to cover taxes related to the vesting of restricted stock units.

Brian T. Powl, Chief Commercial Officer of Kura Oncology, sold 1,583 shares of common stock to cover taxes related to a vesting of restricted stock units.

Mollie Leoni, Chief Medical Officer of Kura Oncology, reported the acquisition of restricted stock units and stock options.

Kura Oncology's Chief Scientific Officer, Francis Burrows, was granted options to purchase 185,000 shares of common stock.

Thomas Doyle, SVP of Finance & Accounting at Kura Oncology, reports the acquisition of common stock and stock options, along with adjustments to his holdings, as per a recent SEC Form 4 filing.

Teresa Brophy Bair, Chief Legal Officer of Kura Oncology, reports the acquisition of restricted stock units and options in Kura Oncology.

Brian Powl, Chief Commercial Officer of Kura Oncology, reports the acquisition of restricted stock units and options, as well as the disposal of common stock.

Kathleen Ford, Chief Operating Officer of Kura Oncology, reports the acquisition of stock options.

Troy Edward Wilson, President and CEO of Kura Oncology, Inc., was granted options to purchase 625,000 shares of common stock on January 2, 2025.

Kura Oncology's Chief Operating Officer, Kathleen Ford, acquired 526 shares of common stock through the company's Employee Stock Purchase Plan.

Michael Vasconcelles, a director at Kura Oncology, acquired options to purchase common stock in the company on September 13, 2024.

Mary T. Szela, a director of Kura Oncology, acquired options to purchase 26,000 shares of common stock on June 5, 2024.

Diane L. Parks, a director at Kura Oncology, acquired 26,000 stock options on June 5, 2024, exercisable for common stock.

Director Carol Schafer acquired options to purchase 26,000 shares of Kura Oncology stock on June 5, 2024.

Director Thomas Malley acquired options to purchase 26,000 shares of Kura Oncology stock on June 5, 2024.

Director Faheem Hasnain of Kura Oncology, Inc. acquired 26,000 stock options on June 5, 2024, according to a Form 4 filing with the SEC.

Director Helen Collins reports acquisition of 26,000 stock options in Kura Oncology, Inc.

Teresa Brophy Bair, Chief Legal Officer of Kura Oncology, reports a sale of 2,615 shares and an acquisition of 2,615 shares of common stock on May 20, 2024.